These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7738926)

  • 1. Use of the GnRH agonist stimulation test in the diagnosis of ovarian remnant syndrome. A report of three cases.
    Scott RT; Beatse SN; Illions EH; Snyder RR
    J Reprod Med; 1995 Feb; 40(2):143-6. PubMed ID: 7738926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ovarian remnant syndrome: diagnostic difficulties and management].
    Fat BC; Terzibachian JJ; Bertrand V; Leung F; de Lapparent T; Grisey A; Maillet R; Riethmuller D
    Gynecol Obstet Fertil; 2009 Jun; 37(6):488-94. PubMed ID: 19457698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian remnant syndrome.
    Magtibay PM; Nyholm JL; Hernandez JL; Podratz KC
    Am J Obstet Gynecol; 2005 Dec; 193(6):2062-6. PubMed ID: 16325616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian remnant syndrome: etiology, diagnosis, treatment and impact of endometriosis.
    Kho RM; Abrao MS
    Curr Opin Obstet Gynecol; 2012 Aug; 24(4):210-4. PubMed ID: 22729094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment.
    Barbieri RL
    J Reprod Med; 1998 Mar; 43(3 Suppl):287-92. PubMed ID: 9564663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laparoscopic management of benign serous neoplasia arising from persistent ovarian remnant.
    Mahdavi A; Kumtepe Y; Nezhat F
    J Minim Invasive Gynecol; 2007; 14(5):654-6. PubMed ID: 17848331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian remnant syndrome: difficulties in diagnosis and management.
    Price FV; Edwards R; Buchsbaum HJ
    Obstet Gynecol Surv; 1990 Mar; 45(3):151-6. PubMed ID: 2190128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ovarian remnant syndrome].
    Fushiki H
    Nihon Rinsho; 2006 Jun; Suppl 2():468-70. PubMed ID: 16817444
    [No Abstract]   [Full Text] [Related]  

  • 10. Ovarian remnant syndrome.
    Magtibay PM; Magrina JF
    Clin Obstet Gynecol; 2006 Sep; 49(3):526-34. PubMed ID: 16885659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome.
    Kho RM; Magrina JF; Magtibay PM
    Fertil Steril; 2007 May; 87(5):1005-9. PubMed ID: 17478171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program.
    Toth TL; Awwad JT; Veeck LL; Jones HW; Muasher SJ
    J Reprod Med; 1996 May; 41(5):321-6. PubMed ID: 8725756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian remnant excision necessitating resection of the anterior hypogastric system.
    Unger JB; Paul RA
    Am J Obstet Gynecol; 2001 Jan; 184(2):235-6. PubMed ID: 11174511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a gonadotropin-releasing hormone agonist in the evaluation of postmenopausal virilization due to ovarian hyperthecosis. A case report.
    Koroscil TM; Harter SB; Ouweleen J; Blauer KL
    J Reprod Med; 1996 Apr; 41(4):259-62. PubMed ID: 8728079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidogenic acute regulatory protein in ovarian follicles of gonadotropin-stimulated rats is regulated by a gonadotropin-releasing hormone agonist.
    Irusta G; Parborell F; Peluffo M; Manna PR; Gonzalez-Calvar SI; Calandra R; Stocco DM; Tesone M
    Biol Reprod; 2003 May; 68(5):1577-83. PubMed ID: 12606484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.